Apr 28, 20221 min readDLBCL: Unmet Needs in an Evolving Treatment Landscape ~ 5/18/22 @ Abe & Louie'sInterested? Email Todd directly at todd.boudreau@adctherapeutics.com. ADC0000290 Invitation.pdfDownload PDF • 266KB
Interested? Email Todd directly at todd.boudreau@adctherapeutics.com. ADC0000290 Invitation.pdfDownload PDF • 266KB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
Comments